
Clinical trials data (NCT05468619) shows completed Phase 1 neonatal valacyclovir study, providing pharmacokinetic data for optimized dosing. FDA drug approvals list multiple acyclovir formulations from various manufacturers, indicating established safety profile. Neonatal-specific dosing based on valacyclovir prodrug conversion could improve outcomes in congenital herpes simplex infection while minimizing toxicity.
IPFS: QmW52rNk73mH3eNzMYzyr7JKwVt1FsyZ9Nk9VyAtqRmyva. TX: 0x38a9dd64e112eaf70d7b70c402749346cbcafbf1cac852f1f51a06ed41c83710. CC0.
drug repurposing, herpes, MedicOath, repurposing
drug repurposing, herpes, MedicOath, repurposing
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
